![]() ![]() Subramanian is committed to giving back to his community, a testament to his dedication to scientific advancement and social responsibility. Subramanian is dedicated to training the next generation of scientists and making a difference in people's lives. Subramanian is at the forefront of developing clinical-grade engineered exosomes to treat advanced-stage colorectal cancer patients. ![]() He serves as the section Editor-in-Chief of the journal Vaccines and the Associate section Editor-in-Chief of Cancers. As a co-founder and Chief Scientific Officer of EV Therapeutics Inc., Dr. Subramanian's extensive publication record, including over 120 peer-reviewed articles, attests to his high-quality research and impact. These findings have immense clinical relevance, offering new insights into treating advanced-stage colorectal cancer.ĭr. Subramanian and his team have revealed a previously unknown mechanism affecting T cell costimulation in colorectal cancer by identifying the immune suppression mediated by cancer- secreted exosomes. Subramanian's research has shed light on how cancer cells and the gut microbiome collaborate to suppress the immune response in patients with colorectal cancer. His current research focuses on understanding how cancer cells and gut microbiome manipulate the anti-tumor immune response in colorectal cancer. Subramanian has established an internationally recognized cancer research program focused on deciphering the molecular mechanisms of immune evasion in cancer. Subramanian completed his postdoctoral fellowship at Stanford University and joined the faculty at the University of Minnesota in 2007. ![]()
0 Comments
Leave a Reply. |